C
Takeda Pharmaceutical Company Limited
TAK
$14.81
-$0.385-2.54%
C
Hold
1/31/2025Downgrade
Takeda Pharmaceutical Company Limited (TAK) was downgraded to C- from C on 1/31/2025 due to a noticeable decline in the valuation index, growth index and total return index. EBIT declined 97.56% from $1.63B to $39.68M, earnings per share declined from $0.3848 to $0.0969, and total revenue declined 5.18% from $7.91B to $7.5B.
Takeda Pharmaceutical Company Limited (TAK) was downgraded to C- from C on 1/31/2025 due to a noticeable decline in the valuation index, growth index and total return index. EBIT declined 97.56% from $1.63B to $39.68M, earnings per share declined from $0.3848 to $0.0969, and total revenue declined 5.18% from $7.91B to $7.5B.
C
Hold
11/20/2024Downgrade
Takeda Pharmaceutical Company Limited (TAK) was downgraded to C from C+ on 11/20/2024 due to a decline in the total return index and volatility index.
Takeda Pharmaceutical Company Limited (TAK) was downgraded to C from C+ on 11/20/2024 due to a decline in the total return index and volatility index.
C
Hold
11/5/2024Upgraded
Takeda Pharmaceutical Company Limited (TAK) was upgraded to C+ from C on 11/5/2024 due to an increase in the volatility index.
Takeda Pharmaceutical Company Limited (TAK) was upgraded to C+ from C on 11/5/2024 due to an increase in the volatility index.
C
Hold
11/4/2024Upgraded
Takeda Pharmaceutical Company Limited (TAK) was upgraded to C from C- on 11/4/2024 due to a substantial increase in the valuation index, growth index and total return index. Operating cash flow increased 73.01% from $1.09B to $1.89B, EBIT increased 31.7% from $1.23B to $1.63B, and total revenue increased 2.09% from $7.75B to $7.91B.
Takeda Pharmaceutical Company Limited (TAK) was upgraded to C from C- on 11/4/2024 due to a substantial increase in the valuation index, growth index and total return index. Operating cash flow increased 73.01% from $1.09B to $1.89B, EBIT increased 31.7% from $1.23B to $1.63B, and total revenue increased 2.09% from $7.75B to $7.91B.
C
Hold
8/23/2024Upgraded
Takeda Pharmaceutical Company Limited (TAK) was upgraded to C- from D+ on 8/23/2024 due to an increase in the volatility index and total return index.
Takeda Pharmaceutical Company Limited (TAK) was upgraded to C- from D+ on 8/23/2024 due to an increase in the volatility index and total return index.
D
Sell
8/1/2024Downgrade
Takeda Pharmaceutical Company Limited (TAK) was downgraded to D+ from C- on 8/1/2024 due to a large decline in the growth index, valuation index and efficiency index. Operating cash flow declined 41.78% from $1.88B to $1.09B.
Takeda Pharmaceutical Company Limited (TAK) was downgraded to D+ from C- on 8/1/2024 due to a large decline in the growth index, valuation index and efficiency index. Operating cash flow declined 41.78% from $1.88B to $1.09B.
C
Hold
4/11/2024Downgrade
Takeda Pharmaceutical Company Limited (TAK) was downgraded to C- from C on 4/11/2024 due to a decline in the total return index.
Takeda Pharmaceutical Company Limited (TAK) was downgraded to C- from C on 4/11/2024 due to a decline in the total return index.
C
Hold
2/5/2024Upgraded
Takeda Pharmaceutical Company Limited (TAK) was upgraded to C from C- on 2/5/2024 due to a noticeable increase in the growth index. Earnings per share increased from -$0.2124 to $0.4519, EBIT increased 308.1% from -$341.56M to $710.78M, and total revenue increased 4.26% from $7.22B to $7.53B.
Takeda Pharmaceutical Company Limited (TAK) was upgraded to C from C- on 2/5/2024 due to a noticeable increase in the growth index. Earnings per share increased from -$0.2124 to $0.4519, EBIT increased 308.1% from -$341.56M to $710.78M, and total revenue increased 4.26% from $7.22B to $7.53B.
C
Hold
10/27/2023Downgrade
Takeda Pharmaceutical Company Limited (TAK) was downgraded to C- from C on 10/27/2023 due to a significant decline in the growth index, valuation index and volatility index. Earnings per share declined from $0.4162 to -$0.2125, EBIT declined 62.55% from $1.29B to $481.31M, and total revenue declined 6.39% from $7.71B to $7.22B.
Takeda Pharmaceutical Company Limited (TAK) was downgraded to C- from C on 10/27/2023 due to a significant decline in the growth index, valuation index and volatility index. Earnings per share declined from $0.4162 to -$0.2125, EBIT declined 62.55% from $1.29B to $481.31M, and total revenue declined 6.39% from $7.71B to $7.22B.
C
Hold
7/31/2023Downgrade
Takeda Pharmaceutical Company Limited (TAK) was downgraded to C from C+ on 7/31/2023 due to a noticeable decline in the growth index, solvency index and total return index. Operating cash flow declined 69.68% from $2.22B to $673.25M, the quick ratio declined from 0.49 to 0.46, and EBIT declined 6.02% from $1.36B to $1.27B.
Takeda Pharmaceutical Company Limited (TAK) was downgraded to C from C+ on 7/31/2023 due to a noticeable decline in the growth index, solvency index and total return index. Operating cash flow declined 69.68% from $2.22B to $673.25M, the quick ratio declined from 0.49 to 0.46, and EBIT declined 6.02% from $1.36B to $1.27B.
C
Hold
4/10/2023Upgraded
Takeda Pharmaceutical Company Limited (TAK) was upgraded to C+ from C on 4/10/2023 due to a substantial increase in the growth index, volatility index and total return index. Earnings per share increased from $0.2858 to $0.5381, operating cash flow increased 67.67% from $1.6B to $2.68B, and EBIT increased 37.88% from $756.15M to $1.04B.
Takeda Pharmaceutical Company Limited (TAK) was upgraded to C+ from C on 4/10/2023 due to a substantial increase in the growth index, volatility index and total return index. Earnings per share increased from $0.2858 to $0.5381, operating cash flow increased 67.67% from $1.6B to $2.68B, and EBIT increased 37.88% from $756.15M to $1.04B.
C
Hold
12/27/2022Upgraded
Takeda Pharmaceutical Company Limited (TAK) was upgraded to C from C- on 12/27/2022 due to an increase in the dividend index, total return index and volatility index.
Takeda Pharmaceutical Company Limited (TAK) was upgraded to C from C- on 12/27/2022 due to an increase in the dividend index, total return index and volatility index.
C
Hold
2/28/2022Upgraded
Takeda Pharmaceutical Company Limited (TAK) was upgraded to C- from D+ on 2/28/2022 due to an increase in the total return index and volatility index.
Takeda Pharmaceutical Company Limited (TAK) was upgraded to C- from D+ on 2/28/2022 due to an increase in the total return index and volatility index.
D
Sell
2/11/2022Downgrade
Takeda Pharmaceutical Company Limited (TAK) was downgraded to D+ from C- on 2/11/2022 due to a decline in the dividend index, solvency index and volatility index. Debt to equity increased from 0.81 to 0.83.
Takeda Pharmaceutical Company Limited (TAK) was downgraded to D+ from C- on 2/11/2022 due to a decline in the dividend index, solvency index and volatility index. Debt to equity increased from 0.81 to 0.83.
C
Hold
11/18/2021Downgrade
Takeda Pharmaceutical Company Limited (TAK) was downgraded to C- from C on 11/18/2021 due to a decline in the volatility index, total return index and valuation index.
Takeda Pharmaceutical Company Limited (TAK) was downgraded to C- from C on 11/18/2021 due to a decline in the volatility index, total return index and valuation index.
C
Hold
11/3/2021Upgraded
Takeda Pharmaceutical Company Limited (TAK) was upgraded to C from C- on 11/3/2021 due to an increase in the dividend index, valuation index and efficiency index.
Takeda Pharmaceutical Company Limited (TAK) was upgraded to C from C- on 11/3/2021 due to an increase in the dividend index, valuation index and efficiency index.
C
Hold
8/6/2021Downgrade
Takeda Pharmaceutical Company Limited (TAK) was downgraded to C- from C on 8/6/2021 due to a decline in the volatility index and total return index.
Takeda Pharmaceutical Company Limited (TAK) was downgraded to C- from C on 8/6/2021 due to a decline in the volatility index and total return index.
C
Hold
2/11/2021Upgraded
Takeda Pharmaceutical Company Limited (TAK) was upgraded to C from C- on 2/11/2021 due to a significant increase in the growth index, valuation index and volatility index. Earnings per share increased from $0.0241 to $0.5595, EBIT increased 76.07% from $803.54M to $1.41B, and total revenue increased 7.7% from $7.44B to $8.01B.
Takeda Pharmaceutical Company Limited (TAK) was upgraded to C from C- on 2/11/2021 due to a significant increase in the growth index, valuation index and volatility index. Earnings per share increased from $0.0241 to $0.5595, EBIT increased 76.07% from $803.54M to $1.41B, and total revenue increased 7.7% from $7.44B to $8.01B.
C
Hold
10/30/2020Downgrade
Takeda Pharmaceutical Company Limited (TAK) was downgraded to C- from C on 10/30/2020 due to a significant decline in the growth index, valuation index and efficiency index. Earnings per share declined from $0.4901 to $0.0241, net income declined 95.04% from $767.53M to $38.05M, and EBIT declined 51.46% from $1.66B to $803.54M.
Takeda Pharmaceutical Company Limited (TAK) was downgraded to C- from C on 10/30/2020 due to a significant decline in the growth index, valuation index and efficiency index. Earnings per share declined from $0.4901 to $0.0241, net income declined 95.04% from $767.53M to $38.05M, and EBIT declined 51.46% from $1.66B to $803.54M.
C
Hold
10/22/2020Upgraded
Takeda Pharmaceutical Company Limited (TAK) was upgraded to C from C- on 10/22/2020 due to an increase in the valuation index and volatility index.
Takeda Pharmaceutical Company Limited (TAK) was upgraded to C from C- on 10/22/2020 due to an increase in the valuation index and volatility index.
C
Hold
10/7/2020Downgrade
Takeda Pharmaceutical Company Limited (TAK) was downgraded to C- from C on 10/7/2020 due to a decline in the total return index and volatility index.
Takeda Pharmaceutical Company Limited (TAK) was downgraded to C- from C on 10/7/2020 due to a decline in the total return index and volatility index.
C
Hold
8/13/2020Upgraded
Takeda Pharmaceutical Company Limited (TAK) was upgraded to C from C- on 8/13/2020 due to a significant increase in the valuation index, growth index and solvency index. Earnings per share increased from $0.0101 to $0.4901, EBIT increased 279.6% from -$1.23B to $2.22B, and the quick ratio increased from 0.66 to 0.7.
Takeda Pharmaceutical Company Limited (TAK) was upgraded to C from C- on 8/13/2020 due to a significant increase in the valuation index, growth index and solvency index. Earnings per share increased from $0.0101 to $0.4901, EBIT increased 279.6% from -$1.23B to $2.22B, and the quick ratio increased from 0.66 to 0.7.
C
Hold
8/7/2020Downgrade
Takeda Pharmaceutical Company Limited (TAK) was downgraded to C- from C on 8/7/2020 due to a significant decline in the valuation index, growth index and solvency index. EBIT declined 184.39% from $1.46B to -$1.23B, earnings per share declined from $0.0548 to $0.0101, and total revenue declined 10.35% from $7.91B to $7.09B.
Takeda Pharmaceutical Company Limited (TAK) was downgraded to C- from C on 8/7/2020 due to a significant decline in the valuation index, growth index and solvency index. EBIT declined 184.39% from $1.46B to -$1.23B, earnings per share declined from $0.0548 to $0.0101, and total revenue declined 10.35% from $7.91B to $7.09B.
C
Hold
7/31/2020Upgraded
Takeda Pharmaceutical Company Limited (TAK) was upgraded to C from C- on 7/31/2020 due to a significant increase in the valuation index, growth index and total return index. Earnings per share increased from $0.0101 to $0.4901, EBIT increased 211.84% from -$1.23B to $1.38B, and total revenue increased 5.23% from $7.09B to $7.46B.
Takeda Pharmaceutical Company Limited (TAK) was upgraded to C from C- on 7/31/2020 due to a significant increase in the valuation index, growth index and total return index. Earnings per share increased from $0.0101 to $0.4901, EBIT increased 211.84% from -$1.23B to $1.38B, and total revenue increased 5.23% from $7.09B to $7.46B.
C
Hold
6/26/2020Upgraded
Takeda Pharmaceutical Company Limited (TAK) was upgraded to C- from D+ on 6/26/2020 due to an increase in the valuation index, dividend index and efficiency index.
Takeda Pharmaceutical Company Limited (TAK) was upgraded to C- from D+ on 6/26/2020 due to an increase in the valuation index, dividend index and efficiency index.
D
Sell
2/20/2020Downgrade
Takeda Pharmaceutical Company Limited (TAK) was downgraded to D+ from C- on 2/20/2020 due to a decline in the volatility index.
Takeda Pharmaceutical Company Limited (TAK) was downgraded to D+ from C- on 2/20/2020 due to a decline in the volatility index.
C
Hold
2/6/2020Downgrade
Takeda Pharmaceutical Company Limited (TAK) was downgraded to C- from C on 2/6/2020 due to a noticeable decline in the growth index, valuation index and dividend index. Earnings per share declined from $0.3212 to $0.0548, and operating cash flow declined 35.8% from $2.05B to $1.32B.
Takeda Pharmaceutical Company Limited (TAK) was downgraded to C- from C on 2/6/2020 due to a noticeable decline in the growth index, valuation index and dividend index. Earnings per share declined from $0.3212 to $0.0548, and operating cash flow declined 35.8% from $2.05B to $1.32B.
C
Hold
1/10/2020Upgraded
Takeda Pharmaceutical Company Limited (TAK) was upgraded to C from C- on 1/10/2020 due to an increase in the total return index and volatility index.
Takeda Pharmaceutical Company Limited (TAK) was upgraded to C from C- on 1/10/2020 due to an increase in the total return index and volatility index.
C
Hold
11/5/2019Upgraded
Takeda Pharmaceutical Company Limited (TAK) was upgraded to C- from D+ on 11/5/2019 due to an increase in the dividend index, total return index and solvency index. The quick ratio increased from 0.7 to 0.83, and debt to equity declined from 1.14 to 1.04.
Takeda Pharmaceutical Company Limited (TAK) was upgraded to C- from D+ on 11/5/2019 due to an increase in the dividend index, total return index and solvency index. The quick ratio increased from 0.7 to 0.83, and debt to equity declined from 1.14 to 1.04.
D
Sell
8/2/2019Downgrade
Takeda Pharmaceutical Company Limited (TAK) was downgraded to D+ from C- on 8/2/2019 due to a significant decline in the valuation index, growth index and solvency index. Debt to equity increased from 1.12 to 1.14.
Takeda Pharmaceutical Company Limited (TAK) was downgraded to D+ from C- on 8/2/2019 due to a significant decline in the valuation index, growth index and solvency index. Debt to equity increased from 1.12 to 1.14.
C
Hold
7/16/2019Downgrade
Takeda Pharmaceutical Company Limited (TAK) was downgraded to C- from C on 7/16/2019 due to a decline in the total return index, valuation index and volatility index.
Takeda Pharmaceutical Company Limited (TAK) was downgraded to C- from C on 7/16/2019 due to a decline in the total return index, valuation index and volatility index.
C
Hold
7/1/2019Upgraded
Takeda Pharmaceutical Company Limited (TAK) was upgraded to C from C- on 7/1/2019 due to an increase in the valuation index, dividend index and solvency index. Debt to equity declined from 1.22 to 1.12.
Takeda Pharmaceutical Company Limited (TAK) was upgraded to C from C- on 7/1/2019 due to an increase in the valuation index, dividend index and solvency index. Debt to equity declined from 1.22 to 1.12.
C
Hold
4/18/2019Downgrade
Takeda Pharmaceutical Company Limited (TAK) was downgraded to C- from C on 4/18/2019 due to a decline in the volatility index.
Takeda Pharmaceutical Company Limited (TAK) was downgraded to C- from C on 4/18/2019 due to a decline in the volatility index.
C
Hold
4/3/2019Upgraded
Takeda Pharmaceutical Company Limited (TAK) was upgraded to C from C- on 4/3/2019 due to an increase in the volatility index, total return index and growth index. EBIT increased 52.11% from $655.52M to $997.09M, operating cash flow increased 19.03% from $693.88M to $825.96M, and total revenue increased 14.59% from $3.86B to $4.43B.
Takeda Pharmaceutical Company Limited (TAK) was upgraded to C from C- on 4/3/2019 due to an increase in the volatility index, total return index and growth index. EBIT increased 52.11% from $655.52M to $997.09M, operating cash flow increased 19.03% from $693.88M to $825.96M, and total revenue increased 14.59% from $3.86B to $4.43B.
C
Hold
12/28/2018None
Takeda Pharmaceutical Company Limited (TAK) was downgraded to C- from U on 12/28/2018.
Takeda Pharmaceutical Company Limited (TAK) was downgraded to C- from U on 12/28/2018.
NYSE
04/04/2025 3:47PM Eastern
Quotes delayed
